Business Wire

CA-VERIMATRIX

20.4.2022 17:47:11 CEST | Business Wire | Press release

Share
Mexico’s Megacable Selects Verimatrix Streamkeeper and XTD Products To Further Strengthen Security

Regulatory News:

Verimatrix , (Euronext Paris: VMX) (Paris:VMX), the leader in powering the modern connected world with people-centered security, today announced that Megacable , one of Mexico’s largest telecommunications companies, selected a suite of Verimatrix products and technologies to fortify its enterprise defenses; Verimatrix XTD (Extended Threat Defense), Streamkeeper Watermarking , Streamkeeper Edge Authenticator and App Shield .

Megacable, the first company in Mexico to offer quadruple-play services (cable television, broadband internet, fixed telephony and mobile telephony), has millions of subscribers using the media company’s apps running on unmanaged devices. The company was well aware that extended endpoints at the app level could be weaponized at any time by attackers to attack their enterprise defenses, and they wanted to find a way to expand their defense beyond the traditional perimeter. Additionally, it’s no secret that the media & entertainment industry is seeing a rise in industrial-scale piracy attacks on content distribution networks, and they selected Verimatrix specifically for its distinguished reputation in both threat defense and anti-piracy.

Megacable products set to use Verimatrix threat defense and anti-piracy solutions include the Xview+ app, Android TV set-top boxes, select Megacable.com.mx payment/financial services, as well as other internal Megacable apps.

Hackers are continually looking for new ways to infiltrate enterprise security walls and Verimatrix XTD consistently identifies and closes vulnerabilities. Verimatrix XTD is an enterprise SaaS solution that will monitor Megacable’s mobile apps and devices connected to their cloud services.

Verimatrix XTD’s features include:

  • Shielding Apps – With self-defending mobile application shielding, Verimatrix provides organizations with layers of protections such as obfuscation, environmental checks​ and anti-tamper, plus 24/7 monitoring with immediate detection when an app is under attack with remote shut-down capability.
  • Unmanaged Device Telemetry – Protection from unmanaged devices at the endpoint, such as set-top box receivers, IoT and medical devices, by gaining real-time, continuous threat intelligence utilizing Verimatrix’s zero-code telemetry technology.
  • Monitoring and Early Detection – Better understand the threat profile of your installed base of users, and drill down into the risk score of an individual app instance, with real-time notifications of high-risk events to uncover hidden dangers in your enterprise security wall.
  • Attack Pattern Detection and Prediction – Comprehensive, predictive analysis of cyber threats based on large data sets, artificial intelligence (AI) and machine learning (ML), to recognize patterns, making future predictions to benefit the enterprise.

Having used Verimatrix IPTV and DVB Hybrid content security solutions since 2012, Megacable’s work with Verimatrix is also expanded with the deployment of Watermarking and Edge Authenticator anti-piracy solutions. The unique deployment of Streamkeeper zero-code injection technology into select Megacable set-top boxes is a first for both companies. The process will protect access to the Content Security Network (CDN) without the need for cumbersome, time consuming or expensive integrations, meeting stringent requirements from major studios that require it for 4K Ultra HD content. Megacable may add additional Verimatrix Streamkeeper services to its portfolio of anti-piracy countermeasures in the future.
“Megacable already enjoys robust network security, but by adding Verimatrix XTD and Streamkeeper anti-piracy technologies, we’re creating an even more formible security posture for our company, our content and our customers,” said Gerardo Seifert Arriola, Chief Marketing Officer at Megacable. “We’re pleased to continue working with Verimatrix to provide an excellent user experience while also deploying the latest in security technology to maintain our stance as the regional leader in our industry.”

“Megacable has taken a bold step forward by adding threat defense and anti-piracy technology to their enterprise security stack,” said Asaf Ashkenazi , Chief Operating Officer and President at Verimatrix. “Megacable is now our largest customer to date to commit to deploying Verimatrix Streamkeeper and Verimatrix XTD solutions. The alliance underscores our goal to provide proactive cybersecurity and anti-piracy countermeasures that fortify operators against threats of today and the unforeseen dangers of tomorrow. We’re pleased to continue working with Megacable to provide unique and innovative solutions that boost protections and also help ensure exceptional user experiences no matter how content is accessed.”

About Megacable
Megacable Holdings S.A.B. de C.V. (BMV: MEGA.CPO) is one of the largest telecommunications companies in Mexico and Latin America. It carries out operations in 28 states of the country, with a presence in 400 locations. As of December 31, 2021, it has about 4.2 million unique subscribers, including more than 3.8 million internet subscribers, more than 3.5 million video users and more than 3 million fixed telephony customers. It offers its services through a network of nearly 66,000 kilometers, covering more than 9.5 million homes. Visit www.megacable.com.mx .

About Verimatrix
Verimatrix (Euronext Paris: VMX) helps power the modern connected world with security made for people. We protect digital content, applications, and devices with intuitive, people-centered and frictionless security. Leading brands turn to Verimatrix to secure everything from premium movies and live streaming sports, to sensitive financial and healthcare data, to mission-critical mobile applications. We enable the trusted connections our customers depend on to deliver compelling content and experiences to millions of consumers around the world. Verimatrix helps partners get to market faster, scale easily, protect valuable revenue streams, and win new business. Visit www.verimatrix.com .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Acceleronix, IDEMIA Secure Transactions and Orange Announce Flexible, Single-SKU Manufacturing with Quantum-Safe IFPP4.11.2026 16:44:00 CET | Press release

One SKU. Every market. Connectivity decided at the end of production. Live at electronica 2026. Orange, one of the world’s leading telecom operators, has joined the global quantum-safe In-Factory Profile Provisioning (IFPP) program, jointly launched by Acceleronix and IDEMIA Secure Transactions at MWC Barcelona in February. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104070181/en/ Acceleronix, IDEMIA Secure Transactions and Orange announce flexible, single-SKU manufacturing with quantum-safe IFPP The program enables device makers to build a single product for every market and connect it to the Orange network before it leaves the factory. Acceleronix and IDEMIA Secure Transactions will demonstrate the solution live at electronica 2026, the international electronics trade fair, at Messe München, Hall C2, Stand 601, from 10 to 13 November. Most connected devices share the same weak spot: provisioning and testing on the pr

U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release

If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis

Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release

This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw

Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release

New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra

Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release

Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye